Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer discussed, along with the need for diversification. Cramer highlighted that he is fond of the stock, as he said: “You could own JNJ and Merck with their incredible franchises. You know what? I’m actually particularly fond of JNJ right now. They’re spinning off their […]

Description: JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.

Description: Johnson & Johnson has outpaced the S&P 500 over the past year, and analysts remain optimistic about the healthcare stock's growth potential ahead.

Description: Wondering if Johnson & Johnson stock is a hidden gem or already fully priced? This article will break down everything you need to know about its current value. The share price recently moved up by 11.2% over the last month, contributing to a strong 44.1% year-to-date return and a 38.0% gain over the past year. These changes may indicate growing investor confidence or shifting risk perceptions. Recent headlines indicate that Johnson & Johnson is strengthening its market position with major...

Description: We recently published 10 Best Small-Cap Stocks With Huge Potential According to Reddit as Market Looks Beyond AI Trade. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is among the best small-cap stocks to buy according to Redditors. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best small-cap stocks with huge upside potential according to Redditors. The company is […]

Description: Dividends can help enrich your portfolio for years to come.

Description: These top dividend stocks could intrigue a wide range of investors.

Description: Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

Description: The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.

Description: Extending Medicare reimbursement for cardiac catheter ablation to settings outside the hospital is expected to boost procedure volumes and benefit Abbott, Boston Scientific, J&J and Medtronic.

Description: Ever wondered if Kenvue is a hidden value play or if its recent price is telling us something different? Today, we are unpacking whether the current share price is a bargain or a warning sign for investors. Kenvue’s stock price has caught some attention lately, climbing 4.9% over the last week and jumping 13.5% for the past month. This comes despite a drop of 20.0% year-to-date and 26.5% over the last year. In recent weeks, headlines have highlighted Kenvue’s continued integration efforts...

Description: Johnson & Johnson (JNJ) shares have edged higher over the past month, building on a steady run that has seen the stock advance 17% in the past 3 months. Investors are watching for what comes next as momentum builds. See our latest analysis for Johnson & Johnson. The share price momentum for Johnson & Johnson has been impressive, with steady gains this year suggesting renewed investor confidence as the company continues to navigate a shifting healthcare landscape. Over the past year, the total...

Description: Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.

Description: J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.

Description: The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

Description: As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

Description: Johnson & Johnson (NYSE:JNJ) is a global healthcare company that develops, manufactures, and sells pharmaceutical products and medical devices. It is set to report its Q4 2025 earnings on Jan. 21. Wall Street analysts expect the company to post EPS of ...

Description: Financial foundation toward self-sustained long-term growth established with the closing with HealthCare Royalty (“HCRx”) of a non-dilutive royalty financing valued up to $71 millionProgress in the JNJ-1900 (NBTXR3) global development program announced including first data from a Phase 1 esophageal cancer study sponsored by The University of Texas MD Anderson Cancer Center (“MD Anderson”)Completed the NANORAY-312 sponsorship transfer to Johnson & Johnson in the majority of regionsAdvanced the Cu

Description: Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major bleeding.

Description: CorpGov and IPO Edge are pleased to provide complete video coverage of the fifth annual Palm Beach CorpGov Forum held on Nov. 5-6, featuring keynote speaker Josh Frank, Partner and Co-Chief Investment Officer at Wall Street legend Nelson Peltz’s Trian Fund Management. Mr. Frank discussed Trian’s position for the last six years at Unilever PLC […] The post EXCLUSIVE: Sustainable Value Creation: Keynote Fireside with Trian Fund Management, 5th Palm Beach CorpGov Forum appeared first on CorpGov.

Description: The Hip Replacement industry is poised for substantial growth, projected to reach US$ 10.24 billion by 2033, up from US$ 6.92 billion in 2024, at a CAGR of 4.45% between 2025 and 2033. This expansion is driven by increased awareness of procedures such as hip arthroplasty, which helps alleviate discomfort and enhance mobility for those with severe joint disorders. Factors such as rising obesity, orthopedic issues, and demand for surgical treatments contribute to market growth. Key players driving

Description: It has grown wildly, and it could keep growing.

Description: RVL Pharmaceuticals, Inc and its affiliates (together, "RVL") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.

Description: Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently offered insights on. Cramer discussed the company’s planned acquisition of Kenvue during the episode. He said: “Alright, this is one we’ve talked about a bunch, Kimberly-Clark’s bold, nearly $49 billion bid to buy Kenvue, which is the J&J’s old over-the-counter business that makes Tylenol, […]

Description: Kenvue Inc. (NYSE:KVUE) is one of the stocks on Jim Cramer’s radar recently. During the lightning round, a caller asked if long-term shareholders should be worried. Here’s what Mad Money’s host had to say in response: “Okay, it’s a really important question because I’ve been looking to buy Kimberly. I think the answer is no. […]

Description: Johnson & Johnson's stock narrative has seen a notable development, with the consensus analyst price target rising slightly from $199.56 to $200.82. This adjustment reflects renewed optimism driven by a combination of strong business execution, strategic initiatives such as the planned orthopedics spin-out, and confidence in the company's robust pipeline. Stay tuned to discover how you can monitor future updates to Johnson & Johnson's evolving outlook. Stay updated as the Fair Value for...

Description: Despite PIPE-307’s failure in RRMS, analysts still have hope for the candidate in major depressive disorder (MDD).

Description: A spate of promising news is helping to extend a post-earnings rally for the healthcare giant's shares.

Description: Lilly becomes the first pharmaceutical company to hit that threshold, joining a select club of mostly tech companies.

Description: LLY's expanding AI alliances highlight how pharma-tech partnerships are transforming healthcare and lifting key sector ETFs like XLV.

Description: The medical technology stock is in a consolidation pattern and testing a key level. The biotech had a beat-and-raise quarter.

Description: HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.

Description: The global surgical stapling devices market, valued at $5.23 billion in 2023, is anticipated to grow to $8.32 billion by 2029, with a CAGR of approximately 8%. This growth is propelled by the rising demand for minimally invasive procedures and increased healthcare investments, especially in emerging nations. Market segmentation highlights the dominance of disposable and powered surgical stapling devices due to convenience and enhanced functionality. North America leads, driven by innovative tech

Description: BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.

Description: MIAMI, FL / ACCESS Newswire / November 20, 2025 /OMP, a global leader in supply chain planning solutions, brought together global supply chain executives, technology innovators, and strategic partners at the OMP REAL Conference 2025 in Miami. Held ...

Description: Clarity Eye Centre announced the arrival of Johnson & Johnson's next-generation SILK™ Laser Eye Technology, now available to patients in Hong Kong. The clinic is the first in the city to widely offer the ELITA™ Femtosecond Laser, the advanced system that powers SILK™ (Smooth Incision Lenticule Keratomileusis), ushering in a new era of precision and gentle laser vision correction for myopia, with or without astigmatism.[1]

Description: Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the

Description: Eli Lilly and J&J recently announced partnerships with AI chipmaker Nvidia, pointing to a broader trend of tie-ups to advance drug discovery and improve workflows.

Description: Johnson & Johnson had strong Q3 results and reported an important acquisition.

Description: MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.

Description: Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry

Description: ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.

Description: Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms

Description: Intuitive Surgical's Ion platform represents robust growth potential with strong procedure growth. Clinical trial data demonstrate superiority in diagnostic yield.

Description: In November 2025, Johnson & Johnson announced several major product developments, including new FDA approvals for DARZALEX Faspro in high-risk smoldering multiple myeloma, CAPLYTA as an adjunctive treatment for major depressive disorder, and positive late-stage clinical results for TREMFYA in psoriatic arthritis. These achievements underline Johnson & Johnson's momentum in expanding its pharmaceutical portfolio with treatments targeting significant unmet medical needs across oncology,...

Description: J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.

Description: ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.

Description: J&J this year lost its patent exclusivity for Stelara, its longtime top-selling drug that treats psoriasis and inflammatory bowel disease.

Description: The acquisition brings Halda's candidate HLD-0915, a clinical-stage treatment for prostate cancer, into J&J's oncology portfolio.

Description: Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and post rising estimates.

Description: Deal adds new prostate cancer candidate and supports J&J's long-term oncology strategy.

Description: Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

Description: The Dow Jones index fell on the stock market today. Lithium stocks rose on bullish commentary. Alphabet jumped on a Warren Buffett move but Peter Thiel dumped a key AI stock.

Description: Health care stocks were decreasing late Monday afternoon with the NYSE Health Care Index and the Hea

Description: Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”

Description: The Dow Jones Industrial Average was down, the Nasdaq Composite was higher, and the S&P 500 was roug

Description: (Corrected to add "billion" in headline.) Johnson & Johnson (JNJ) has agreed to buy Halda Therape

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Johnson & Johnson's (JNJ) move to broaden its cancer research portfolio by acquiring Halda Therapeutics for $3 billion, Sinclair Broadcast Group (SBGI) taking a stake in broadcasting company E.W. Scripps (SSP), and bubble-wrap inventor Sealed Air (SEE) agreeing to go private in a deal with private equity firm CD&R. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Johnson & Johnson (JNJ) has agreed to buy Halda Therapeutics for $3.05 billion in cash as the health

Description: BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.

Description: Macy's climbs after a Zacks upgrade as multiple portfolios showcase strong gains across UNFI, Monster Beverage and other standout stocks.

Description: Johnson & Johnson has agreed to buy clinical-stage biotechnology company Halda Therapeutics for $3.05 billion in cash in a deal that bolsters the healthcare giant’s oncology pipeline.

Description: Halda to be acquired by Johnson & Johnson for $3.05 billion in cashHalda recently presented positive Phase 1/2 data for HLD-0915 in metastatic castration-resistant prostate cancer and continues rapid clinical developmentAdditional RIPTAC™ programs in development for major solid tumor types and other serious diseases NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics announced today that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquir

Description: Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks.1 These data were presented at the Inflammatory Skin Disease Summit (ISDS) 2025.

Description: NEW BRUNSWICK, N.J., November 17, 2025--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC™) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. The transaction is expected to close within the next few months, su

Description: Eli Lilly's surging GLP-1 momentum and Johnson & Johnson's diversified strength set up a compelling 2025 showdown for investors weighing growth vs. stability.

Description: The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s shown promise in early-stage testing.

Description: Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Passive Income Stocks to Buy Right Now. On November 12, Scotiabank’s Louise Chen began coverag‍e of ten large-cap biopharma companies and took a positiv‍e‍ st‌ance‌ on the sect‍or, n‌oting th⁠at‌ years of lagging performance compared with other‍ industrie‌s and majo‍r indices ma‍y offe⁠r in​vestors an appealing […]

Description: Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.

Description: Health care stocks fell late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Hea

Description: US equity indexes were mixed ahead of Friday's close amid selective dip-buying in technology and inf

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Pfizer's fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has climbed slightly as well. Analysts note this shift reflects a blend of enthusiasm for new pipeline additions alongside prudent awareness of industry headwinds. Stay tuned to discover how evolving market developments continue to shape Pfizer's investment outlook and what to watch going forward. Analyst Price Targets don't always capture the full story. Head over to our Company...

Description: Bristol said it had decided to stop one of its ongoing Phase 3 trials testing an experimental blood thinner called milvexian.

Description: Major U.S. equities indexes were mixed Friday afternoon, following a sharp decline Thursday fueled by a selloff of tech stocks.

Description: US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec

Description: Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s breakthrough medicine, as he remarked: “We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why […]

Description: A Texas judge will weigh Texas Attorney General Ken Paxton's bid to block Kenvue's (KVUE) November d

Description: Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial

Description: Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently put under a microscope. Cramer showed quite a bullish sentiment toward the company’s stock, as he remarked: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… Amgen’s […]

Description: Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently put under a microscope. Cramer said that “you’d do very well” owning the stock, as he stated: “If you want to venture beyond what we call the CPG, consumer packaged goods, world, I think you’d do very well with owning J&J or Amgen… […]

Description: We recently published Jim Cramer Discussed These 25 Stocks In An Important Show About AI Spending. Johnson & Johnson (NYSE:JNJ) is one of the stocks Jim Cramer recently discussed. Johnson & Johnson (NYSE:JNJ) is one of the biggest healthcare and pharmaceutical companies in the world. The firm recently spun off its orthopedic business, and Cramer […]

Description: Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.

Description: If you're a new investor looking for some long-term opportunities, don't overlook these top healthcare buys.

Description: These top dividend payers could enrich a long-term investor's portfolio.

Description: BeOne Medicines is Wednesday's IBD Stock Of The Day. The IBD 50 biotech is breaking out after a record-breaking quarter.

Description: Bank of America came up with 16 names that investors should consider buying. Renaissance Macro threw out a couple of sector ideas, too.

Description: Bayer's Q3 earnings surged on Crop Science strength, offsetting pricing and currency headwinds across divisions.

Description: Precision medicine and next-gen biologics are transforming patient care. Despite cost-related challenges, key players like AbbVie, Johnson & Johnson, and Bristol-Myers Squibb are leading innovations.Dublin, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The "Psoriatic Arthritis Market - A Global and Regional Analysis: Focus on Drug Type and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. The growing prevalence of autoimmune diseases, particularly among individu

Description: ABBV's growth engine keeps humming as Skyrizi and Rinvoq together now power more than 40% of total revenues and drive new market share gains.

Description: These companies are demonstrating their ability to deal with significant business risks.

Description: He bought Nvidia at $101, rode the AI wave to solid gains, and then dumped everything. In a post on the Stocks subreddit, a 25-year-old investor said he sold his entire portfolio—including top performers like Nvidia (NASDAQ:NVDA), Broadcom (NASDAQ:AVGO), and Alphabet (NASDAQ:GOOG, GOOGL)) —because he's convinced the market is sitting on a ticking time bomb. "I have SOLD IT ALL because I fear that it might crash because of all the uncertainty and overvaluation," he wrote. Despite gaining around 1

Description: J&J's MedTech sales rose 5.6% in Q3, fueled by cardiovascular strength and strategic portfolio shifts toward high-growth markets.

Description: Wondering if Johnson & Johnson is a bargain or overpriced right now? You are not alone. Plenty of investors are questioning whether its shares offer value at today's levels. The stock has shown solid momentum lately, climbing 3.7% in the last week and 1.6% over the past month, with a striking 34.6% year-to-date run. Driving some of this share price action are developments such as the company's recent acquisition in the medtech space and expanded strategic partnerships, both of which have...

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied. This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Johnson & Johnson (JNJ) just secured back-to-back FDA approvals for two therapies, representing a meaningful expansion in both its oncology and neuropsychiatry portfolios. These developments could open up additional opportunities for long-term growth. See our latest analysis for Johnson & Johnson. These approvals have come amid a stretch of strong momentum for Johnson & Johnson, with the stock delivering a robust 9.05% share price gain over the last quarter and an impressive 25.45% total...

Description: Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies due to rising PAH prevalence and greater awareness, alongside enhanced diagnostic capabilities. The shift towards personalized medicine and digital health tools also offers avenues for optimizing treatment efficacy and patient management. Pulmonary Arterial Hypertension Market Pulmonary Arterial Hypertension Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Pulmonary Art

Description: The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Description: President and CEO Joni Odum has driven plans to boost revenue at Firstline Brands to $50M within the next five years.

Description: Haleon plc (NYSE:HLN) is one of the stocks Jim Cramer recently discussed. Cramer highlighted the stock’s struggles, as he commented: “With Kimberly-Clark shelling out nearly $49 billion to buy Kenvue, which was originally J&J’s over-the-counter medicine business, I think it’s time to check in with Haleon, the former consumer business of GlaxoSmithKline and Pfizer… Oh, […]

Description: Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer recently shared thoughts on. Cramer showed his disappointment in the company’s schizophrenia medicine sales, as he commented: “Look, I, my Charitable Trust owns Bristol, looks like a mistake because I, I believed in Cobenfy, which is a, a pretty good product, but it’s not […]

Description: In recent days, Recursion Pharmaceuticals announced a major leadership transition appointing Najat Khan, Ph.D., as CEO effective January 1, 2026, while also securing a milestone payment from Roche and Genentech for delivering a whole-genome microglial immune cell map. This leadership change brings an executive with significant AI-driven drug discovery experience at Johnson & Johnson, coinciding with cumulative partner milestone payments at the company surpassing US$500 million. We'll now...

Description: This approval marks a milestone for high-risk sMM patients, but analyst Biswajit Podder notes that there are caveats to its future success.

Description: These five Dividend Kings offer investors a solid source of passive income, and are among the safest picks in the group.

Description: Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval of a new indication for DARZALEX Faspro® (daratumumab and hyaluronidase-fihj) co-formulated with ENHANZE®, as single agent treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). DARZALEX Faspro® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multi

Description: Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM).1 DARZALEX FASPRO® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multiple myeloma.

Description: Johnson & Johnson's stock price target has seen a slight increase, with the Fair Value Estimate rising from $198.03 to $199.56 following recent analyst updates. This adjustment reflects the company's strong operational performance, a positive outlook on business portfolio changes, and encouraging signals from its innovative medicine segment. Stay tuned to discover how you can continue tracking the evolving narrative around Johnson & Johnson's shares as the story develops. Analyst Price...

Description: Caplyta’s MDD label extension marks the first approval since J&J acquired the drug in a $14.6bn buyout.

Description: Attorney General Ken Paxton filed a motion in a Texas District court on Wednesday to prevent Kenvue

Description: The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.

Description: Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. The approval – the first under J&J leadership following its acquisition of Intra-Cellular Therapies, Inc. – provides patients with a safe and effective new treatment option that can enable a path to remission. CAPLYTA® makes it easy to start and stay on treatmen

Description: Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s key to achieving the $5 billion in annualized sales the company expects.

Description: INCHEON, Korea, November 06, 2025--Samsung Bioepis has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, in Europe.

Description: Zimmer Biomet, the maker of knee and hip replacements, missed on quarterly sales estimates and lowered the top end of its outlook for full-year organic revenue growth.

Description: Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Description: We recently published 11 Latest Stocks Jim Cramer Talked About. Kimberly-Clark Corporation (NASDAQ:KMB) is one of the stocks Jim Cramer recently discussed. Along with OpenAI’s Amazon deal, Kimberly-Clark Corporation (NASDAQ:KMB) also made headlines after it announced that it would acquire household and personal products company Kenvue for $48.7 billion. Cramer discussed Kimberly-Clark Corporation (NASDAQ:KMB)’s CEO […]

Description: HALO posts strong third-quarter results with earnings and revenues topping estimates and raises 2025 guidance on robust royalty growth.

Description: Kenvue is under the microscope from the Trump administration, though Kimberly-Clark sees a $32bn horizon.

Description: The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an

Description: The deal, expected to close in the second half of 2026, comes as Kenvue's Tylenol political fight is heating up.

Description: Combined company aims to become global health leader by 2026.

Description: In the past week, Johnson & Johnson unveiled a series of positive clinical updates and regulatory milestones for key pipeline candidates, including icotrokinra and nipocalimab, across multiple immunology and dermatology indications. The announcements featured favorable long-term efficacy and safety data, new head-to-head trials, and expanded FDA designations, indicating pipeline strength and broadening commercial opportunities. One key insight is the mounting preference among patients and...

Description: The proposed biosimilar to J&J’s Simponi was rejected by the FDA due to manufacturing concerns.

Description: PARIS, November 04, 2025--Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted its 510(k) application to the U.S. Food and Drug Administration (FDA). The company’s debut follows positive results from its initial first-in-human study.

Description: Kimberly-Clark shares suffered their biggest one-day drop since the 1980s after the Huggies diapers maker agreed to buy Kenvue. Shares in the Tylenol maker leapt. At the close of trading: Kimberly-Clark's stock fell 15% to $102.

Description: Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors Philippe Schaison Phillipe Schaison, PharmaD, to has been appointed to serve on The BeautyHealth Company Board of Directors. LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment of global aesthetics leader, Philippe Schaison, PharmaD, to its Board of

Description: Kimberly-Clark is buying Tylenol maker Kenvue for nearly $50 billion. The cash-and-stock transaction, announced Monday, values Kenvue at an enterprise value of about $48.7 billion, including debt. Under the terms of the deal, Kenvue shareholders will receive $21.01 a share, based on Kenvue’s closing price of $14.37 on Friday.

Description: Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.

Description: The purchase of Kenvue by Kimberly-Clark announced Monday would mark the close of a short, rocky term of independence for the Tylenol maker, which was spun off from Johnson & Johnson in 2023. Kenvue shares have been under pressure since President Trump’s warning that acetaminophen—the active ingredient in Tylenol—is a potential cause of autism. Kenvue has called the claims baseless.

Description: Caroline Woods: Big brands and big money - Kimberly-Clark is buying Kenvue in a nearly $50 billion cash and stock deal. That would put Huggies, Kleenex, Band-Aid, Neutrogena and Tylenol all under one roof. It’s one of the biggest deals on Wall Street this year and a major move for Kimberly-Clark, ...

Description: <body><p>STORY: :: Kimberly-Clark</p><p>Kimberly-Clarke is betting big on the maker of Tylenol, announcing it will acquire parent company Kenvue for more than $40 billion... marking the largest buyout ever among the U.S. consumer goods industry.</p><p>The historic deal comes after U.S. President Donald Trump made remarks about the painkiller at the White House in September, citing unproven claims linking Tylenol use during pregnancy to autism in children.</p><p>:: September 22, 2025</p><p>UPSOUND US PRESIDENT DONALD TRUMP: “Don't take Tylenol. Don't take it. If you just can't, I mean, fight like hell not to take it."</p><p>Shares of Tylenol-parent Kenvue - which also owns Band-Aid and Neutrogena - soared as much as 19% after the deal's announcement, while buyer Kimberly-Clark's shares tumbled about 14%.</p><p>:: File</p><p>Kenvue, which was spun off from Johnson & Johnson in 2023, has struggled for months with weak demand.</p><p>The company fired its CEO in July and said it was undergoing a strategic review of its assets.</p><p>Investor concern over Monday's merger announcement may stem in part from Kenvue's potential legal exposure to private lawsuits alleging it hid Tylenol's supposed link to autism in children.</p><p>U.S. sales of Tylenol fell 11% between September 20 and October 4 after Trump's remarks, according to a BNP Paribas analyst note last month.</p><p>:: Kimberly-Clark</p><p>But the merger does give Kimberly-Clark access to Kenvue's vast portfolio of brands - which also include Aveeno and Neutrogena - with the combined company expected to bring in annual revenues of roughly $32 billion.</p><p>The deal is expected to close in the second half of 2026.</p></body>

Description: Merger brings Huggies, Kleenex, and Tylenol under one roof

Description: Kenvue, the company that makes Tylenol, is fighting on both the political and scientific fronts. The latest blow came from the U.S. Health Secretary, placing even more pressure on Kenvue stock, which has already lost 40% of its value in the last six months. Robert F. Kennedy Jr. recently made ...

Description: Kenvue's value isn't obvious -- but a merged Kenvue and Kimberly-Clark might be a buy.

Description: Kleenex maker’s deal for troubled Johnson & Johnson spinoff comes amid lawsuits and regulatory scrutiny

Description: The deal will create a new consumer health giant, bringing Kenvue under the wing of the maker of Kleenex tissues and Huggies diapers

Description: Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of the combined company. Kenvue shareholders will own about 46% in what is one of the largest corporate takeovers this year.

Description: -Dr. Mates served as the Chairman, Chief Executive Officer, and Co-founder of Intra-Cellular Therapies, a mental health company, from June 2002 until it was acquired by Johnson & Johnson in 2025-HAYWARD, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platf

Description: The deal is valued at $48.7 billion.

Description: Growth is driven by a rising demand for minimally invasive solutions, advances in technology, and increased beauty consciousness. The aging population and a booming MedSpa culture also contribute to market expansion. However, challenges include high costs and regulatory barriers. Major players like Johnson & Johnson and Galderma are key contributors to this evolving sector. Japanese Non-Invasive Aesthetic Treatment Market Japanese Non-Invasive Aesthetic Treatment Market Dublin, Nov. 03, 2025 (GL

Description: Even though Kenvue's stock was already in a tailspin before the FDA warned pregnant woman that Tylenol posed a health risk, there are still some lingering impacts to consider.

Description: Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and

Description: Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.

Description: The global sun care products market is projected to grow at a CAGR of 4.77% between 2024 and 2030, driven by heightened skin health awareness and influencer marketing. Major players like Beiersdorf AG's NIVEA and Johnson & Johnson's Neutrogena are innovating, with products such as NIVEA's bespoke sun protection and Neutrogena's tie-up with John Cena for Ultra Sheer Mineral Sunscreen. North America leads the market, with over 35% share. The sun protection segment holds the largest share, while cr

Description: ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.

Description: Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.

Description: LYON, France, October 31, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today announces the appointment of Yves Decadt as a member of its Board of Directors.

Description: Here are four options for supplementing your retirement.

Description: AbbVie stock dropped Friday after the biopharmaceutical company reported mixed results across its drug portfolios in the third quarter. Shares declined 4.7% to $217.50, putting AbbVie on pace for its lowest same-day percentage decrease since May 14, according to Dow Jones Market Data. Pharma peers traded mixed: Johnson & Johnson fell slightly while Pfizer gained 0.7%.

Description: Broadcom, Johnson & Johnson, and Palantir headline Zacks' latest analyst picks, with AI growth, pharma innovation, and defense tech momentum driving their outlooks.

Description: Broadcom's AI surge, J&J's resilient growth, and Palantir's defense-driven momentum headline today's top analyst reports.

Description: Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: Bristol Myers Squibb hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio. The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion. Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.

Description: RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

Description: On October 10, 2025, Ulta Beauty's Board of Directors appointed Christopher DelOrefice as Chief Financial Officer, effective December 5, 2025, following an extensive leadership career at Becton Dickinson & Company and Johnson & Johnson. The appointment comes as Ulta Beauty prepares for its third-quarter results amidst analyst expectations for a double-digit earnings drop and heightened margin pressures this year. We'll explore how investor focus on Ulta Beauty's upcoming earnings amid margin...

Description: GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.

Description: Johnson & Johnson (NYSE: JNJ) today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVY™ (nipocalimab-aahu) as the FcRn blocker of choice for appropriate gMG patients. The EPIC study design and Vibrance-MG Phase 2/3 long-term extension (LTE) data are among 38 abstracts the Company will present at the 2025 Myasthenia Gravis Foundation of America (MGFA) Scientific Session and the America

Description: Johnson & Johnson (NYSE:JNJ) is included among the Best Dividend Stocks for the Best Retirement Portfolio. On October 22, Free⁠dom Capital Mark‍ets has lowered i⁠ts‍ rating on Johnson & Johnson (NYSE:JNJ) from B‍uy to Hold, even as it raised the stock’s price tar⁠get fro‌m $180 to $19​0 f⁠oll​owing a solid third-qua⁠rte​r⁠ perform⁠ance. The healt‌hcare company […]

Description: Levin Papantonio legal team Levin Papantonio attorneys Cameron Stephenson, Chris Tisi, and Sara Papantonio FORT LAUDERDALE, Fla., Oct. 28, 2025 (GLOBE NEWSWIRE) -- A jury today awarded $20 million to the family of Dr. Alberto A. Casaretto, finding that Johnson & Johnson’s talc-based products caused his fatal mesothelioma. The lawsuit, brought by his son, Alberto Casaretto Jr., alleged that the company’s talc was contaminated with asbestos and that Johnson & Johnson failed to warn consumers. The

Description: Trying to figure out whether to buy, sell, or hold Johnson & Johnson? You are not alone. The stock price has been on a bit of a rollercoaster lately, closing most recently at $190.3. After a dip of 1.8% this past week, J&J is still up an impressive 5.9% over the last month, 32.1% year to date, and 21.6% in the past year. That kind of track record definitely attracts attention from investors searching for stable growth, but the real question is whether the current price makes sense compared to...

Description: The suit alleges that Kenvue hid autism risks of its popular pain reliever despite doctors saying it is safe to take during pregnancy.

Description: Texas joined the Trump administration in claiming Tylenol causes autism. Shares of Kenvue fell 3.2% Tuesday to $14.60 after Texas Attorney General Ken Paxton filed a suit alleging that the maker of Tylenol engaged in deceptive advertising that said the over-the-counter drug was safe to use while pregnant. The suit also named Johnson & Johnson which spun off Kenvue in 2023.

Description: Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on October 21, keeping the associated price target the same at $90. The analyst supported the optimistic rating with the company’s growth potential and the stability of […]

Description: Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including the state of Texas suing Johnson & Johnson (JNJ) and Kenvue (KVUE) over allegations that the companies hid the connections between Tylenol and Autism for pregnant women, D.R. Horton (DHI) topping quarterly home orders estimates, and Trump Media & Technology Group (DJT, DJTWW) offering predictions market features on Truth Social. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Since the turn of the century, the Dogs of the Dow have significantly outperformed the overall market. These five are perfect plays for a slowing economy.

Description: (Update with Kenvue's and Johnson & Johnson's responses to requests for comment from MT Newswires in

Description: They are about as safe as dividends can get.

Description: Intuitive Surgical's Q3 results impress, with da Vinci 5 adoption driving 23% revenue growth, though sustaining this rapid momentum may pose new challenges ahead.

Description: ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.

Description: HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.

Description: As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.

Description: One growth stock, one high-yield stock, and one Dividend King -- you should find something you like here as October draws to a close.

Description: Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Description: J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.

Description: Protagonist Therapeutics (PTGX) said Monday that new data from two clinical studies of its investiga

Description: The company announced a formal plan to explore strategic alternatives for the segment, which has resulted in the spin-off.

Description: Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care. The results, presented at the 2025 Fall Clinical Dermatology Conference, reveal significant unmet needs and a strong preference for oral treatment options that achieve treatment goals with high efficacy and favorable safety.

Description: Johnson & Johnson (NYSE: JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults with moderately to severely active ulcerative colitis (UC). These results underscore the potential of icotrokinra to deliver a combination of therapeutic benefit and a favorable safety profile with once-daily oral dosing and will be featured among Johnson & Johnson's 23 accepted a

Description: Johnson & Johnson (NYSE: JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® (guselkumab) in adults with moderately to severely active Crohn's disease (CD) at two years.1 These findings are among 23 Johnson & Johnson abstracts being presented at the 2025 American College of Gastroenterology Annual Scientific Meeting (ACG).

Description: Investing.com -- Shares of Avidity Biosciences (NASDAQ:RNA) jumped more than 42% in premarket trading on Monday, while Dyne Therapeutics (NASDAQ:DYN) climbed over 20%, after Novartis announced an agreement to buy Avidity for about $12 billion in cash.

Description: If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.

Description: Dividend investing offers a reliable path to passive income and long-term wealth building, especially when stock prices stagnate or decline. Regular payouts provide cash flow regardless of market direction, and reinvesting dividends historically drives much of total return. High-yield stocks, however, carry risks. Yields above 5% often signal underlying issues—declining earnings, high debt, or sector-specific ... 3 Dividend Stocks With Yields Over 5%. Should You Buy?

Description: Looking at high-yield healthcare stocks? These three stand out (but one has a slight skew to its story).

Description: Johnson & Johnson (JNJ) shares have edged mostly sideways over the past week, finishing at $190.40 in the latest session. Investors are weighing the company’s recent performance as revenue and net income both show modest annual growth. See our latest analysis for Johnson & Johnson. Johnson & Johnson’s share price has rallied impressively in 2024, notching a 32.2% year-to-date gain that reflects renewed optimism after a period of volatility. Despite a minor pullback in the past week, momentum...

Description: Johnson & Johnson (NYSE: JNJ) today announced findings from the Phase 2 DAHLIAS study published in The Lancet showing that nipocalimab, an investigational FcRn treatment for Sjögren's disease (SjD), significantly decreased disease activity and severity in patients with moderate-to-severe disease.1

Description: GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.

Description: Hopes of a U.S.-China trade truce are lifting sentiment for healthcare ETFs like XLV, IYH, and VHT, which could gain from easing tariffs and lower costs.

Description: MRK expects new products like Capvaxive, Winrevair, and the Animal Health business to support its top-line growth in the third quarter.

Description: Johnson & Johnson (NYSE: JNJ) today announced new long-term 52-week data from the Phase 3 ICONIC-TOTAL studya evaluating icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 receptor, in adults and pediatric patients 12 years of age and older (adolescents) with plaque psoriasis (PsO) affecting high-impact sites.

Description: PARIS and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along with the tr

Description: Halozyme boosts its 2025 revenue outlook on surging royalties from Darzalex SC, Phesgo and Vyvgart Hytrulo, though partner reliance persists.

Description: MINNETONKA, Minn., October 23, 2025--AngioInsight, a leader in AI-powered cardiovascular diagnostics, today announced the appointment of Shlomi Nachman, former Worldwide Chairman of Johnson & Johnson’s Cardiovascular and Specialty Solutions (CSS), to its Board of Directors. AngioInsight is further announcing initiation of its Series A round of $25M, following the successful closing of its oversubscribed seed funding round. The investment will support the ongoing development of AngioAI+™, the com

Description: The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow

Description: Johnson & Johnson stock has moved back into focus as analysts raise their consensus price target from $185.13 to $198.03. This reflects greater confidence following positive company developments. The upgraded target follows robust quarterly results and optimistic revised guidance, suggesting renewed momentum for the healthcare giant. Stay tuned to discover how you can follow these evolving perspectives and stay ahead of shifts in Johnson & Johnson’s investment narrative. What Wall Street Has...

Description: The former consumer health unit of Johnson & Johnson remains mired in troubles surrounding Tylenol.

Description: Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Description: Industry giants, including AstraZeneca, Johnson & Johnson, General Mills, and Kraft Heinz, to present real-world case studies in Miami MIAMI, FL / ACCESS Newswire / October 22, 2025 /OMP, a global leader in supply chain planning solutions, announced ...

Description: RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors

Description: Joining other honorees such as Adobe, IBM, Johnson & Johnson, and many others. NORTHAMPTON, MA / ACCESS Newswire / October 21, 2025 /Fast Company announced its seventh annual Best Workplaces for Innovators list, recognizing businesses that foster ...

Description: J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.

Description: RA'ANANA, Israel, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced two key leadership appointments that reinforce its global commercialization and governance – the appointment of Mr. Mike Hershkovitz as Vice President of Global Sales of the Company and the appointment of Ms. Sivan Matza as a member of the board of directors

Description: Amazon has grown since it launched as an online bookstore in 1995 to become the dominant player in web hosting 30 years later. Amazon Web Services (AWS) was launched in 2006, and over the last decade, it has become the largest cloud computing provider in the world. AWS generated $107.6 billion in ...

Description: Kenvue Faces a Defining Moment: Leadership Shakeup and Strategic Review Signal Pressure for Change

Description: These three stocks have elevated yields and attractive dividend histories.

Description: Johnson & Johnson (JNJ) said Sunday that its subcutaneous formulation of amivantamab showed an overa

Description: These companies pay durable and steadily rising dividends.

Description: Johnson & Johnson (NYSE:JNJ) today announced promising new results from the Phase 1b/2 OrigAMI-4 study evaluating the efficacy and safety of subcutaneous (SC) amivantamab monotherapy in patients with human papillomavirus (HPV)-unrelated, recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after disease progression on a checkpoint inhibitor and platinum-based chemotherapy. The study used the new subcutaneous formulation of amivantamab, which can be delivered in a five-minute

Description: The Standard & Poor's 500 index rose 1.7% this week as earnings season kicked off on a largely posit

Description: If the combination were to be approved, Tecvayli would expand out from its traditional role in fourth line treatment and beyond.

Description: JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

Description: BOSTON, October 17, 2025--Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors

Description: Combo beats investigator choice in relapsed setting

Description: Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: The funding tranche follows HistoSonics’ $2.25bn acquisition by an investor consortium in August.

Description: Chris Lialios will continue as interim CFO until DelOrefice assumes the position in December 2025

Description: The company raised money from Bezos Expeditions, Thiel Bio and other investors to fund the commercial and clinical expansion of its technology.